NasdaqGS:TWSTBiotechs
Twist Bioscience (TWST) Is Up 19.9% After Raising 2026 Revenue Outlook And Highlighting DNA Platform
In early February 2026, Twist Bioscience reported first-quarter fiscal 2026 revenue of US$103.7 million, up from US$88.71 million a year earlier, while maintaining a quarterly net loss of US$30.51 million and issuing raised revenue guidance for both the second quarter and full fiscal year 2026.
An interesting feature of this update is how Twist’s silicon-based DNA synthesis platform and expanding customer base are underpinning its twelfth consecutive quarter of revenue growth and...